Phibro Animal Health's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Phibro Animal Health (PAHC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Phibro Animal Health vs Its Competitors
- TTM: Trailing 12-month revenue of 1,517M vs 81,106M combined for its competitors (1.8% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+4.6% annualized vs trailing 12 months), vs holding steady (+0.8%) for its tracked peer group.
- Growth: Phibro Animal Health generated 4.4% revenue growth year over year in Q4 2026, vs 4.8% for its competitors combined.
- Profitability: Its 5.5% net margin compares with -2.9% for the peer group.
- Scale: Phibro Animal Health ranks #124 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Phibro Animal Health accounted for 1.9% of combined revenue among its tracked peer group, down from 1.9% a year earlier.
- Peer differentiation: Revenue per employee of $0.58M compares with $0.82M for the peer group (0.7x).
- Structure: Phibro Animal Health operates in the following segments: Animal Health, Mineral Nutrition, Performance Products; and reports the following subsidiaries: Western Magnesium Corp..
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PAHC Sales vs. its Competitors, Q4 2026
Phibro Animal Health reported revenue growth of 4.40 % year on year in Q4 2026, below its competitors' combined revenue growth of 4.80 %.
With a net margin of 5.47 %, Phibro Animal Health achieved higher profitability than its competitors (-2.90 %).
Phibro Animal Health generated 1.90 % of the combined sales of its peer group, down from 1.91 % a year earlier.
API endpoints for this dataset
Phibro Animal Health vs. its Competitors, Q4 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Phibro Animal Health reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Phibro Animal Health and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Phibro Animal Health Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Phibro Animal Health's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 4.4% for Phibro Animal Health. Phibro Animal Health's share of combined industry revenue moved from 0.08% to 0.08%, a gain of 0.00 percentage points.
Phibro Animal Health's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Phibro Animal Health Corporation | Yes | Yes | Yes | No |
| Competitors combined (3) | ||||
| High-Confidence Competitors (1) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PAHC Stock Performance relative to its Competitors
PAHC Stock Performance relative to High-Confidence Competitors
PAHC Stock Performance relative to Similar-Size Competitors
PAHC Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Merck and Co Inc | 282.9% | Outperformed |
| 2 | Elanco Animal Health Incorporated | 282.9% | Outperformed |
| 3 | Zoetis Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Phibro Animal Health's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Phibro Animal Health's Comment on Competition and Industry Peers
Publicly Traded Peers of Phibro Animal Health Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Phibro Animal Health Corporation |
1,350.17 | 1,516.86 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
 Zoetis Inc |
33,165.38 | 9,517.00 |
 Elanco Animal Health Incorporated |
13,021.87 | 5,020.00 |
| SUBTOTAL | 409,935.82 | 82,622.86 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Phibro Animal Health Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Phibro Animal Health's Competitors Named by the Company
Competitive relationships identified from Phibro Animal Health reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Zivo Bioscience Inc | Company report | 85% |
| Elanco Animal Health Incorporated | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Zoetis Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Phibro Animal Health's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Phibro Animal Health's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Phibro Animal Health Corporation | Animal Health 75.77 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Zoetis Inc | United States 52.11 % |
| Elanco Animal Health Incorporated | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Phibro Animal Health's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Phibro Animal Health Corporation | 1,350 | 582,288 | 38,280 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| Zoetis Inc | 33,165 | 656,345 | 180,414 |
| Elanco Animal Health Incorporated | 13,022 | 507,071 | -20,101 |
| PEERS TOTAL | 408,586 | 815,956 | 56,207 |
Phibro Animal Health's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Phibro Animal Health Corporation | US 55.86 % |
| Merck and Co Inc | EMEA 21.50 % |
| Elanco Animal Health Incorporated | Non-US 51.54 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Phibro Animal Health's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Phibro Animal Health's industry classification, broader than the peer set above. Market cap in millions of $.Phibro Animal Health ranks #124 of 495 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 124 | Phibro Animal Health Corporation | 1,350 | 0.02 % |
Market cap and industry share for the rest of Phibro Animal Health's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Phibro Animal Health's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 119 | Nuvation Bio Inc | 1,451 | -18.09 % |
| 120 | Damora Therapeutics Inc | 1,448 | 269.44 % |
| 121 | Uniqure N v | 1,437 | -18.84 % |
| 122 | Innoviva Inc | 1,402 | 7.60 % |
| 123 | Tyra Biosciences Inc | 1,234 | 12.3% |
| 124 | Phibro Animal Health Corporation | 1,350 | -14.01 % |
| 125 | Anaptysbio Inc | 1,234 | 12.3% |
| 126 | Kailera Therapeutics Inc | 1,234 | 12.3% |
| 127 | Opko Health Inc | 1,234 | 12.3% |
| 128 | Mineralys Therapeutics Inc | 1,234 | 12.3% |
| 129 | Lb Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Phibro Animal Health's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Phibro Animal Health's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 33.79 % | 37.89 % (avg) | -4.1 pp |
| Operating Margin | 12.82 % | industry median | +13.5 pp |
| EBITDA Margin | 17.01 % | -6.23 % (avg) | +23.2 pp |
| Capital Intensity (Capex / Revenue) | 3.90 % | 7.58 % (avg) | -3.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Phibro Animal Health's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 17.3x | 26.6x | -9.3x |
| EV / EBITDA | 9.2x | 15.9x | -6.8x |
| P/B | 5.1x | 4.3x | +0.9x |
| Return on Equity | 29.66 % | industry aggregate | 13.31 % |
| Return on Invested Capital | 12.41 % | -9.83 % (avg) | 22.24 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Phibro Animal Health's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 7.03 % | -3.07 % | -1.89 % | 10.20 % | 10.54 % | 0.86 % | 12.72 % | 32.57 % |
| Operating Margin | 12.06 % | 7.92 % | 9.40 % | 8.66 % | 7.37 % | 5.84 % | 7.38 % | 11.52 % |
| Return on Invested Capital | 13.72 % | 7.82 % | 9.10 % | 8.45 % | 6.99 % | 5.32 % | 8.13 % | 11.32 % |
| P/E | 18.7x | 26.0x | 17.8x | 15.8x | 15.1x | 31.0x | 48.3x | 18.0x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Phibro Animal Health's Strategic Group Map
Phibro Animal Health is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Phibro Animal Health's trailing-12-month revenue growth of 17.1% and operating margin of 12.8% compares with an average of 11.8% growth and 12.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Phibro Animal Health sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Phibro Animal Health's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Phibro Animal Health falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Phibro Animal Health's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.90 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Phibro Animal Health's dedicated Suppliers and Customers pages, not here.
Phibro Animal Health's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Phibro Animal Health falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Phibro Animal Health's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 13.5 points above the industry median.
- Return on equity 13.3 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+4.6% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Trades at a lower P/E than the industry average (17.3x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Phibro Animal Health's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Phibro Animal Health Corporation | 0.22 | 2.99 | 2.09 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Zoetis Inc | 0.68 | 3.23 | 2.25 |
| Elanco Animal Health Incorporated | 0.31 | 2.18 | 0.75 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Phibro Animal Health's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Phibro Animal Health Corporation | Q2 2026 | +4.4 % | +26.0 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Zoetis Inc | Q2 2026 | +0.3 % | -4.8 % |
| Elanco Animal Health Incorporated | Q2 2026 | +10.2 % | +390.9 % |
| PEERS TOTAL | +4.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Phibro Animal Health's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Phibro Animal Health Corporation | Q2 2026 | -2.4 % | +43.6 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Zoetis Inc | Q2 2026 | +1.4 % | -21.5 % |
| Elanco Animal Health Incorporated | Q2 2026 | +8.0 % | -42.1 % |
Phibro Animal Health's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Phibro Animal Health Corporation | 7.01% | 8.11% | 29.66% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Zoetis Inc | 17.19% | 19.44% | 68.87% |
| Elanco Animal Health Incorporated | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Phibro Animal Health's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Phibro Animal Health Corporation | 13.51 | 0.89 |
| Merck and Co Inc | 118.32 | 5.44 |
| Zoetis Inc | 13.00 | 3.48 |
| Elanco Animal Health Incorporated | - | 2.59 |
| PEERS AVERAGE | 72.09 | 4.96 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.